Carlos A. Sariol to Antibodies, Viral
This is a "connection" page, showing publications Carlos A. Sariol has written about Antibodies, Viral.
Connection Strength
2.246
-
Sariol CA, Serrano-Collazo C, Ortiz EJ, Pantoja P, Cruz L, Arana T, Atehortua D, Pabon-Carrero C, Espino AM. Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population. Viruses. 2021 11 30; 13(12).
Score: 0.719
-
Sariol CA, Gonz?lez-Mart?nez J, Arana T, Gascot S, Su?rez E, Maldonado E, Gerald MS, Rodr?guez M, Kraiselburd EN. Differential distribution of antibodies to different viruses in young animals in the free-ranging rhesus macaques of Cayo Santiago. J Med Primatol. 2006 Dec; 35(6):369-75.
Score: 0.254
-
Espino AM, Armina-Rodriguez A, Alvarez L, Ocasio-Malav? C, Ramos-Nieves R, Rodriguez Martin? EI, L?pez-Marte P, Torres EA, Sariol CA. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Viruses. 2024 Jan 26; 16(2).
Score: 0.209
-
Sariol CAA, Pantoja P, Serrano-Collazo C, Rosa-Arocho T, Armina-Rodr?guez A, Cruz L, Stone ETT, Arana T, Climent C, Latoni G, Atehortua D, Pabon-Carrero C, Pinto AKK, Brien JDD, Espino AMM. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. Viruses. 2021 09 30; 13(10).
Score: 0.178
-
P?rez-Guzm?n EX, Pantoja P, Serrano-Collazo C, Hassert MA, Ortiz-Rosa A, Rodr?guez IV, Giavedoni L, Hodara V, Parodi L, Cruz L, Arana T, White LJ, Mart?nez MI, Weiskopf D, Brien JD, de Silva A, Pinto AK, Sariol CA. Time elapsed between Zika and dengue virus infections affects antibody and T cell responses. Nat Commun. 2019 09 20; 10(1):4316.
Score: 0.154
-
Sariol CA, Nogueira ML, Vasilakis N. A Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance Zika Disease? Trends Microbiol. 2018 03; 26(3):186-190.
Score: 0.136
-
Pantoja P, P?rez-Guzm?n EX, Rodr?guez IV, White LJ, Gonz?lez O, Serrano C, Giavedoni L, Hodara V, Cruz L, Arana T, Mart?nez MI, Hassert MA, Brien JD, Pinto AK, de Silva A, Sariol CA. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun. 2017 06 23; 8:15674.
Score: 0.132
-
Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, Wallace D, Gordon GS, Stinchcomb DT. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. J Infect Dis. 2016 May 15; 213(10):1562-72.
Score: 0.119
-
Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, de Silva AM, Baric RS. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio. 2015 Oct 13; 6(5):e01461-15.
Score: 0.117
-
Young E, Yount B, Pantoja P, Henein S, Meganck RM, McBride J, Munt JE, Baric TJ, Zhu D, Scobey T, Dong S, Tse LV, Martinez MI, Burgos AG, Graham RL, White L, DeSilva A, Sariol CA, Baric RS. A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. Nat Commun. 2023 03 13; 14(1):1371.
Score: 0.049
-
Karger AB, Brien JD, Christen JM, Dhakal S, Kemp TJ, Klein SL, Pinto LA, Premkumar L, Roback JD, Binder RA, Boehme KW, Boppana S, Cordon-Cardo C, Crawford JM, Daiss JL, Dupuis AP, Espino AM, Firpo-Betancourt A, Forconi C, Forrest JC, Girardin RC, Granger DA, Granger SW, Haddad NS, Heaney CD, Hunt DT, Kennedy JL, King CL, Krammer F, Kruczynski K, LaBaer J, Lee FE, Lee WT, Liu SL, Lozanski G, Lucas T, Mendu DR, Moormann AM, Murugan V, Okoye NC, Pantoja P, Payne AF, Park J, Pinninti S, Pinto AK, Pisanic N, Qiu J, Sariol CA, Simon V, Song L, Steffen TL, Stone ET, Styer LM, Suthar MS, Thomas SN, Thyagarajan B, Wajnberg A, Yates JL, Sobhani K. The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. mSphere. 2022 08 31; 7(4):e0019322.
Score: 0.047
-
Chen RE, Smith BK, Errico JM, Gordon DN, Winkler ES, VanBlargan LA, Desai C, Handley SA, Dowd KA, Amaro-Carambot E, Cardosa MJ, Sariol CA, Kallas EG, S?kaly RP, Vasilakis N, Fremont DH, Whitehead SS, Pierson TC, Diamond MS. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021 11 10; 29(11):1634-1648.e5.
Score: 0.044
-
Stauft CB, Song Y, Gorbatsevych O, Pantoja P, Rodriguez IV, Futcher B, Sariol CA, Wimmer E. Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2. Virology. 2019 11; 537:237-245.
Score: 0.038
-
Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A. 2014 Feb 04; 111(5):1939-44.
Score: 0.026
-
White LJ, Sariol CA, Mattocks MD, Wahala M P B W, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI, de Silva A, Johnston RE. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J Virol. 2013 Mar; 87(6):3409-24.
Score: 0.024